We applied licorice flavonoid oil (LFO) to high-fat diet-induced obese C57BL/6J mice and investigated its effect. LFO contains hydrophobic flavonoids obtained from licorice by extraction with ethanol. The oil is a mixture of medium-chain triglycerides, having glabridin, a major flavonoid of licorice, concentrated to 1.2% (w/w). Obese mice were fed on a high-fat diet containing LFO at 0 (control), 0.5%, 1.0%, or 2.0% for 8 weeks. Compared with mice in the control group, those in the 1% and 2% LFO groups efficiently reduced the weight of abdominal white adipose tissues and body weight gain. A histological examination revealed that the adipocytes became smaller and the fatty degenerative state of the hepatocytes was improved in the 2% LFO group. A DNA microarray analysis of the liver showed up-regulation of those genes for beta-oxidation and down-regulation of those for fatty acid synthesis in the 2% LFO group. These findings suggest that LFO prevented and ameliorated diet-induced obesity via the regulation of lipid metabolism-related gene expression in the liver.
We applied licorice flavonoid oil (LFO) to high-fat diet-induced obese C57BL/6J mice and investigated its effect. LFO contains hydrophobic flavonoids obtained from licorice by extraction with ethanol. The oil is a mixture of medium-chain triglycerides, having glabridin, a major flavonoid of licorice, concentrated to 1.2% (w/w). Obese mice were fed on a high-fat diet containing LFO at 0 (control), 0.5%, 1.0%, or 2.0% for 8 weeks. Compared with mice in the control group, those in the 1% and 2% LFO groups efficiently reduced the weight of abdominal white adipose tissues and body weight gain. A histological examination revealed that the adipocytes became smaller and the fatty degenerative state of the hepatocytes was improved in the 2% LFO group. A DNA microarray analysis of the liver showed up-regulation of those genes for beta-oxidation and down-regulation of those for fatty acid synthesis in the 2% LFO group. These findings suggest that LFO prevented and ameliorated diet-induced obesity via the regulation of lipid metabolism-related gene expression in the liver.
Key words: licorice flavonoid; diet-induced obesity; DNA microarray; metabolic syndrome Licorice, the root of the leguminous Glycyrrhiza plant species, has been used for over 4000 years since ancient Egyptian times, and is one of the most frequently employed botanicals. 1) Licorice and its aqueous extract containing glycyrrhizin, a major component of licorice, are also used as flavoring and sweetening agents in food products. There are several species of licorice, including Glycyrrhiza uralensis Fischer, G. glabra Linne, and G. inflata Batalin, each of which contains speciesspecific flavonoids. 1) Glabridin, a major isoflavan occurring in G. glabra, is one of the well-defined flavonoids of licorice, having antinephritic and radical-scavenging activities 2, 3) and inhibiting serotonin re-uptake. 4) It also has anti-Helicobacter pylori activity 5) and antioxidative activity, [6] [7] [8] [9] [10] [11] as well as melanogenesis-and inflammation-inhibiting activities. 12) Obesity usually results from an energy imbalance due to excessive energy storage and insufficient energy expenditure, and develops a number of risk factors for cardiovascular diseases, arteriosclerosis, osteoarthritis, and certain cancers. The clustering of several cardiovascular risk factors for abdominal obesity, dyslipidemia, glucose intolerance, and hypertension in the same individual is called the metabolic syndrome. 13, 14) Adipocytes are not merely energy-storing cells but also secrete a variety of adipocytokines such as leptin, tumor necrosis factor-, plasminogen activator inhibitor-1, resistin, and adiponectin. 15, 16) Hypertrophy of visceral adipose tissue accompanies excessive secretion of some of these adipocytokines, and induces insulin resistance which causes type 2 diabetes mellitus, dyslipidemia, hypertension, and cardiovascular diseases. 17) Abdominal obesity occurring by an accumulation of visceral fat is thus a primary cause of the metabolic syndrome.
A diet-induced obese model has been used to investigate human obesity, since it reproduces human obesity better than genetic obese models. C57BL/6J mice are obesity-prone and, when fed on a high-fat diet, develop obesity, hyperglycemia, and hyperlipidemia. 18, 19) This model has thus often been used for investigating obesity, diabetes, and dyslipidemia. C57BL/ 6J mice fed on a high-fat diet differ from those fed on a normal diet in terms of the expression levels of various genes. [20] [21] [22] Genes encoding enzymes participating in lipid metabolism as markers of adipocyte differentiation, enzymes involved in detoxification, and structural components of the cytoskeleton are up-regulated in adipose tissue of C57BL/6J mice fed on a high-fat diet. 20) The genes involved in fatty acid catabolism, ketone body synthesis, and stress responses are upregulated, while those involved in lipogenesis and cholesterol synthesis are down-regulated in the liver of C57BL/6J mice fed on a high-fat diet. 22) Meanwhile, DNA microarray technology has become available, providing an understanding of the possible mechanisms behind diet-induced obesity. [23] [24] [25] We have investigated the effects of hydrophobic flavonoids from G. glabra by using licorice flavonoid oil (LFO). 26) LFO was prepared by further extracting an ethanolic licorice extract with medium-chain triglycerides (MCT) and adjusting the glabridin concentration up to 1.2% (w/w). 26) We found that, when LFO was given to obese diabetic KK-A y mice fed on a high-fat diet, their body weight gain and abdominal adipose tissue weight, as well as the increase in their blood glucose level, were both suppressed. 26) Since KK-A y mice become seriously obese and genetically develop hyperglycemia with aging, they are used as a model of type 2 diabetes. On the other hand, C57BL/6J mice gradually develop obesity and leptin resistance during the feeding of a high-fat diet, and are used as a model of diet-induced obesity in humans. 18 ) Accordingly, we demonstrate the abdominal fat-lowering effect of LFO in diet-induced obese C57BL/6J mice and its effects on hepatic gene expression by DNA microarray technology, since the liver is one of the major organs of lipid metabolism and insulin action for fat storage and release in response to the energy balance.
Materials and Methods
Preparation of licorice flavonoid oil (LFO). LFO was prepared as described in our previous report. 26) Roots of licorice, Glycyrrhiza glabra Linne, were extracted twice with a five-fold volume of 95% ethanol to obtain an ethanol extract, which was then filtered and concentrated. The concentrate was dissolved in a medium-chain triglyceride mixture (MCT) constituted by octanoic acid and decanoic acid (99:1; Riken Vitamin Co., Ltd., Tokyo, Japan), evaporated to remove the ethanol, and filtered. The obtained oil containing licorice flavonoids was used as LFO, with its glabridin concentration adjusted to 1.2% (w/w). Consequently, LFO contained MCT at 88% (w/w) and a licorice extracted-derived solid fraction at approximately 12% (w/w). The polyphenol content of LFO was approximately 10% when assayed by the Folin-Ciocalteau method, 27) using authentic glabridin (Wako Pure Chemical Industries, Osaka, Japan) as a standard compound.
Experiments with diet-induced obese mice. Female C57BL/6J mice (Clea Japan, Tokyo, Japan) were housed in an animal laboratory controlled to the temperature of [20] [21] [22] [23] [24] C and humidity of 45-65% with a 12-h (7:30-19:30) light/dark cycle. The mice aged 8 weeks were fed on a high-fat diet (Table 1 ; Oriental Yeast, Co., Tokyo, Japan) for 8 weeks, and divided into four groups of ten mice each by body weight stratification. They were then fed on a high-fat diet containing LFO at 0.5%, 1.0%, or 2.0% for an additional 8 weeks. A similar, but LFO-deleted diet, was used as a control. The MCT concentration in each diet was set at 2%. The mice were permitted ad libitum access to food and water. The food intake was measured per week on a cage basis, and individual animals were weighed per week. After the feeding period, the non-fasted mice were sacrificed without affliction under diethyl ether anesthesia at 9:00-10:30 to collect their blood, mesenteric, perirenal, and periuterine white adipose tissues (WAT), liver, kidney, and spleen samples. Serum was separated by a standard centrifugation method and stored at À80 C until needed for measurement of the insulin, leptin and adiponectin levels. The liver samples were immediately immersed in RNAlater (Ambion, Austin, TX, USA) and kept at À80 C until total RNA was prepared. Experiments were performed according to the Guidelines for the Care and Use of Experimental Animals of the Japanese Association for Laboratory Animal Science.
Measurements of serum insulin, leptin, and adiponectin. The serum insulin, leptin, and adiponectin levels were measured by using a mouse insulin EIA kit and mouse leptin EIA kit (Morinaga Institute of Biological Science; Yokohama, Japan), and mouse/rat adiponectin ELISA kit (Otsuka Pharmaceutical Co., Tokyo, Japan) according to the manufacturers' protocols.
Histological examination of the liver and mesenteric WAT. The liver and mesenteric WAT in the control and 2% LFO groups were each fixed in 10% (v/v) buffered formalin and embedded in paraffin wax. Tissue sections, 4 mm each in thickness, were stained with hematoxylin and eosin (HE), prior to microscopic observation.
Preparation of total RNA. Each of the total RNA extracts from the liver samples in the control and 2% LFO groups was treated with TRIzol (Invitrogen Japan, Tokyo, Japan) and purified with an RNeasy Mini Kit (Qiagen, Tokyo, Japan) according to the manufacturer's protocol. The quality of the consequently isolated total RNA was checked by using an 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and RNA6000 Nano Kit (Agilent Technologies).
DNA microarray analysis of the liver. To determine the difference in hepatic gene expression between the control and 2% LFO groups, the isolated total RNA was submitted to a DNA microarray analysis with a G4121A Mouse Oligo Microarray (Agilent Technologies) for more than 20,000 genes. Three mice in each group were selected by tissue weight. Equal amounts of isolated total RNA from these three mice in each group were then combined and used for the DNA microarray analysis. Total RNA (10 mg) was annealed with an oligo-dT primer, and a reverse transcriptase reaction was performed with aminoallyl-dUTP to obtain cDNA incorporating aminoallyl-dUTP. The obtained cDNA was labeled with Cy3 fluorescent dye for the control or Cy5 for the LFO group. The array was hybridized at 60 C for 17 hr in a hybridization buffer containing equal amounts of Cy3-and Cy5-labeled cDNA, and then scanned with a DNA Microarray Scanner (Agilent Technologies). The data were analyzed by using Feature Extraction software (Agilent Technologies). The fluorescence intensity (F.I.) of the negative control as a background was subtracted from the fluorescence intensity of each spot. The validity of each spot was determined based on the Agilent criterion that a signal should be more than 2.6-fold the standard deviation of the background and sufficiently uniform. Normalization between the Cy3 and Cy5 signals was performed by the global normalization method. Data with a lower fluorescence intensity (< 10 F.I.) were excluded, and genes with a greater than 2-fold F.I. difference ratio between the Cy3 and Cy5 signals were selected.
Quantitative real-time PCR analysis. Quantitative real-time PCR was performed according to the TaqMan probe method. Appropriate primers and FAM (carboxyfluorescein)-labeled TaqMan probes for mouse Ehhadh (enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase), Acly (ATP citrate lyase), Acas2 (acetyl-CoA synthetase 2), and Gapdh (glyceraldehyde-3-phosphate dehydrogenase) were obtained from a commercial source (TaqMan Gene Expression Assays; Applied Biosystems Japan, Tokyo, Japan). The respective TaqMan Gene Expression Assays identities for mouse Ehhadh, Acly, Acas2 and Gapdh were Mm01343141 m1, Mm00652520 m1, Mm00480101 m1, and Mm99999915 g1. Total RNA was extracted, as already mentioned, from each of the seven remaining mice (excepting the three mice submitted to the DNA microarray analysis). Reverse transcription (RT) was carried out with 1 mg of the total RNA in a 50 ml reaction mixture using a High Capacity cDNA Archive kit (Applied Biosystems Japan). A universal master mix (Applied Biosystems Japan) containing the PCR buffer, MgCl 2 , dNTPs, and thermally stable AmpliTaq Gold DNA polymerase was used in the PCR reactions. The PCR mixture containing the primers, TaqMan probes, RNase/DNase-free water, and 1 ml of the RT product was added to the universal master mix to set a final volume at 50 ml per reaction. The reaction mixture was incubated at 95 C for 10 min to activate the AmpliTaq Gold DNA polymerase and then run for 40 cycles at 95 C for 15 s and 60 C for 60 s in the ABI prism 7000 Sequence Detection System (Applied Biosystems Japan). The PCR results were analyzed with ABI SDS software (Applied Biosystems Japan). The relative expression levels of each sample were calibrated by the comparative Ct method, using those of Gapdh as an endogenous control.
Statistical analysis. Animal experiment data were analyzed with the SAS/STAT computerized statistical analysis program (SAS Institute, Cary, NC, USA). When statistical significance was detected by one-way ANOVA, Dunnett's multiple-comparison test was applied to identify the significance. Differences are considered significant at p < 0:05. For the quantitative real-time PCR data, the significance of differences in the mean values was evaluated by Student's t-test at p < 0:05. Each value in the text is presented as the mean AE S.D.
Results
Experiments with diet-induced obese mice After obesity had been induced in female C57BL/6J mice by feeding with a high-fat diet for 8 weeks, their average body weight was 26:9 AE 2:3 g. The mice were then fed with a high-fat diet containing LFO for an additional 8 weeks. While the body weight of the control group increased to 33:1 AE 2:6 g, feeding with 1% and 2% LFO suppressed the body weight increase (p < 0:01) (Fig. 1) . In the control group, the body weight gain was 6:2 AE 2:2 g/8 wk ( Table 2 ). The body weight gains in the 1% and 2% LFO groups were found to be significantly lower (p < 0:01) than that in the control group in a dose-dependent manner ( Table 2 ). The addition of LFO to the diet did not affect the food intake (Fig. 2) . From the food intake and body weight data, the daily LFO consumption by the 0.5%, 1%, and 2% LFO groups was calculated as 386, 804, and 1640 mg/kg body weight/day, respectively. The weights of the mesenteric, perirenal, and periuterine WAT were significantly lower (p < 0:05 or 0.01) in the 1% and 2% LFO groups than in the control group (Table 2) . In contrast, no significant differences were apparent among these groups in terms of the weights of the liver, kidney, and spleen (data not shown). Moreover, LFO did not affect the locomotor activity when evaluated by supermex (Muromachi Kikai Co., Tokyo, Japan) (data not shown). The serum leptin and insulin levels were lower in the 1% and 2% LFO groups (p < 0:01) than in the control group (Table 2) , whereas there was no significant difference in the serum adiponectin level between the control and any of the LFO groups (Table 2 ).
Histological examination of mesenteric WAT and the liver
The effects of LFO consumption on the adipocyte size and lipid droplets in the hepatocytes were demonstrated by a histopathological examination of mesenteric WAT and the liver. Each section (Fig. 3 and Fig. 4 ) was selected to show the representative findings for the control and 2% LFO groups. The adipocyte diameter in the 2% LFO group was reduced to approximately onehalf or one-third of that in the control group (Fig. 3) . Moreover, lipid droplets in the hepatocytes were abundant in the control group, but not in the 2% LFO group (Fig. 4) . However, no adverse histological findings such as inflammation due to LFO consumption were apparent in mesenteric WAT and the liver.
DNA microarray analysis of the liver
To characterize the mechanism for the effect of LFO on the diet-induced obese C57BL/6J mice, the level of gene expression in the liver was compared between the control and 2% LFO groups by the DNA Fig. 1 . Effect of LFO on Body Weight.
Obese C57BL/6J mice were fed on a high-fat diet containing LFO at 0% (filled circles), 0.5% (filled squares), 1% (unfilled circles), and 2% (unfilled squares) for 8 wk, and weighed every week. Each value is the mean AE SD. Fig. 2 . Effect of LFO on Food Intake. Obese C57BL/6J mice were fed on a high-fat diet containing LFO at 0% (filled circles), 0.5% (filled squares), 1% (unfilled circles), and 2% (unfilled squares) for 8 wk. The food intake was measured each week on a cage basis.
Fig. 3. Histological Staining of Mesenteric White Adipose Tissue (WAT).
Mesenteric WAT of the diet-induced obese C57BL/6J mice fed on a high-fat diet containing LFO at 0% (control, left panel) and 2% (right panel) for 8 wk was stained with HE and examined microscopically. The representative sections of mesenteric WAT in the control and 2% LFO groups are shown. The liver of diet-induced obese C57BL/6J mice fed on a high-fat diet containing LFO at 0% (control, left panel) and 2% (right panel) for 8 wk was stained with HE and examined microscopically. The representative sections of the liver in the control and 2% LFO groups are shown. microarray technique. When the genes exhibiting greater than a 2.0-fold difference in expression level between the control and LFO groups were selected and categorized by gene ontology, the respective numbers of upand down-regulated genes were 9 (Table 3 ) and 13 genes (Table 4) . LFO consumption up-regulated the expression level of the genes involved in beta-oxidation and acyl-CoA degradation. These were exemplified by the genes, enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase (Ehhadh) (fold change, 2.09) and acylCoA thioesterase 1 (Acot-1) (fold change, 2.72), respectively. On the other hand, the genes for acetyl-CoA synthesis such as ATP citrate lyase (Acly) and acetylCoA synthetase 2 (Acas2) were decreased to 1/2.11 and 1/2.06, respectively. In addition, pyruvate kinase in the liver and red blood cell (Pklr), a rate-limiting enzyme involved in glycolytic lipogenesis, was down-regulated by LFO consumption.
Real-time PCR analysis
A quantitative real-time PCR analysis was performed to confirm the expression changes of some genes selected by the DNA microarray analysis. We determined the gene expression levels of Ehhadh, Acly, and Acas2 in each of the seven mice (excepting the three mice submitted to the DNA microarray analysis). The result showed that the gene expression level of Ehhadh in the 2% LFO group was significantly increased by 2.49-fold at p < 0:001 (Fig. 5) . On the other hand, the gene expression levels of Acly and Acas2 were significantly decreased to 1/2.51 (p < 0:001) and 1/2.25 (p < 0:001), respectively (Fig. 5) .
Discussion
LFO is a unique food ingredient prepared by further extracting the licorice ethanolic extract with MCT for the purpose of concentrating the hydrophobic polyphenols. It contains 88% MCT and a solid fraction derived from the licorice extract. Almost all the hydrophobic polyphenols in LFO are flavonoids, with glabridin as a typical one.
LFO consumption significantly suppressed the dietinduced increase in abdominal adipose tissue mass comprising the mesenteric, perirenal, and periuterine WAT masses, and the body weight gain was reduced in a dose-dependent manner ( Fig. 1 and Table 2 ). No significant differences were apparent in the weights of the liver, kidney, and spleen. This suggests that the effect of LFO was not due to any toxicity. The effect of LFO on KK-A y mice was also confirmed in our previous report. 26) To reconfirm this with the obesity model, we conducted an in-house study by comparing the effect of the normal diet and the high-fat diet on the body weight of C57BL/6J mice over an observation period of 16 weeks. This resulted in the body weight of the 2% LFO group, when compared to that of the control group, decreasing by 18.8%. The result suggests that LFO efficiently suppressed the high-fat diet-induced obesity. A decrease in size of adipocytes was also observed in the LFO group (Fig. 3) . These findings indicate that LFO could promote lipolysis or suppression of fat accumulation without any toxic effect.
The serum insulin level decreased in a dose-dependent manner, the insulin level of the 2% LFO group being less than half that of the control group (Table 2) . Feeding a high-fat diet has been reported to increase the serum insulin level, inducing insulin resistance in C57BL/6J mice. 29) However, the results of the present study clearly show that LFO consumption suppressed an insulin level increase, even in the case of feeding a highfat diet. Therefore, the decreases in visceral fat and insulin level induced by LFO consumption would reflect an improvement in insulin resistance. It is to be noted that a suppression of the increase in blood glucose level in the type 2 diabetes model KK-A y mice by LFO consumption had been observed in our previous study. 26) Several studies have recently revealed that adipocytes secreted such adipocytokines as leptin and adiponectin as well as merely storing energy. 16, 30) Leptin plays roles in regulating the food intake and energy expenditure, and the serum leptin level is increased with increasing adipose tissue mass. 18) Feeding a high-fat diet to C57BL/6J mice has been reported to increase the serum leptin level by about 6-fold and to cause leptin resistance. 20) Compared with the control group, the serum leptin level in the 2% LFO group was decreased from 35.3 mg/ml to 6.54 mg/ml in accordance with the decrease in adipose tissue mass (Table 2 ). However, there was no difference in food intake between the control and 2% LFO groups (Fig. 2) . This result seems to have been due to the induced leptin resistance of the control mice. Insulin has been reported to be involved in determining the serum leptin level. 29) Therefore, it is likely that a decrease in the serum leptin level would have resulted from decreases in the adipose tissue mass and serum insulin level. Adiponectin contributes to energy homeostasis to modulate glucose and lipid metabolism. This suggests that an increase in circulating adiponectin level would lower the hepatic glucose production 31) and that diet-induced obesity would lead to reducing the expression of adiponectin and its serum level. 32) In addition, it has been reported that the administration of thiazolidinediones (TZDs) as peroxisome proliferator-activated receptor-(PPAR-) ligands increased the expression and secretion of adiponectin, and thereby increased the serum adiponectin level. 33) Our previous study 26) has demonstrated that LFO stimulated human adipocyte differentiation in vitro and had abdominal fat-lowering and hypoglycemic effects on KK-A y mice which were possibly mediated via the activation of PPAR-. However, the present study has shown that there was no significant difference in serum adiponectin level between the control and any of the LFO groups ( Table 2 ), suggesting that LFO might have exerted another abdominal fat-lowering effect on C57BL/6J mice.
The reduced level of lipid droplets in the hepatocytes of the 2% LFO group indicates an improvement of fatty liver induced by the high-fat diet (Fig. 4 ). It appears that LFO consumption probably activated either fatty The changing expression of Ehhadh, Acly, and Acas2 were quantified by a quantitative real-time PCR analysis. The relative expression level of each sample was calibrated by the comparative Ct method, using Gapdh as an endogenous control. Each value is the mean AE SD. Significant differences (p < 0:01) from the control group are asterisked. acid catabolism or inactivated fatty acid synthesis. Ashakumary et al. 34) have reported that the anti-obesity mechanism in the liver involved both the suppression of fatty-acid synthesis and the activation of fatty-acid metabolism. With this as a background, we then directed our study toward investigating the hepatic gene expression change that was determinable by a DNA microarray analysis. This analysis showed that LFO consumption down-regulated Acly and Acas2 involved in the synthesis of acetyl-CoA from citrate and acetate (Table 4) . On the other hand, LFO consumption up-regulated the gene for Ehhadh, a bifunctional enzyme, which is the key enzyme at the late stage of peroxisomal betaoxidation ( Table 3 ). The results obtained from the quantitative real-time PCR analysis correlated well with those from the DNA microarray analysis, suggesting that LFO consumption would suppress fatty-acid synthesis and activate peroxisomal beta-oxidation. A change in the expression of these genes may thus be related to the decrease in amount of fatty acids in the liver due to LFO consumption. This result supports the finding from the histological examination that LFO consumption improved the status of fatty liver. We therefore conclude that the change in fatty acid metabolism in the liver due to a change in the expression of these genes would reflect in whole or in part the anti-obesity mechanism resulting from LFO consumption. A further study of gene expression in other tissues such as the muscle and adipose tissue would provide more important information about the effect of LFO.
In conclusion, this study has demonstrated that LFO consumption suppressed increases in the abdominal adipose tissues and body weight, hyperinsulinemia, and hyperleptinemia induced by feeding a high-fat diet to C57BL/6J mice. The gene expression profiles determined by a DNA microarray analysis suggest that the anti-obesity effects of LFO would have resulted from suppressed fatty acid synthesis and activated fatty acid catabolism in the liver. This would be one of major reasons of LFO consumption for anti-obesity. In considering that an accumulation of visceral fat induces the metabolic syndrome, 35) our findings suggest the possibility that LFO would suppress the accumulation of visceral fat to ameliorate or prevent the metabolic syndrome as a representative lifestyle-related disease caused by an excessive intake of a high-fat diet.
